Breast cancer is a disease where cells in the breast grow out of control. Treatment in the early stages typically involves surgery but there is a chance that the cancer will come back. A challenge is whether to recommend chemotherapy after surgery because of the negative side effects.
Gene expression profiling tests analyze a sample of the breast cancer tissue to identify the presence or absence of certain genes in the cancer cell. This information may help physicians determine the likelihood that the cancer will return after surgery and can help guide decisions about whether a person may benefit from chemotherapy.
This health technology assessment looked at how safe and effective gene expression profiling testing is for people with early-stage invasive breast cancer. It looked at the cost-effectiveness and the budget impact of publicly funding gene expression profiling tests. It also looked at the experiences, preferences, and values of people with early-stage invasive breast cancer.
The assessment was conducted in collaboration with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institute of Health Economics (IHE). CADTH completed a rapid review of the qualitative evidence of patient preferences.
Read the full Health Technology Assessment report for more information.
We reviewed evidence on the use of Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer. Read the latest draft recommendation from Health Quality Ontario and share your feedback.
Date posted: September 24, 2019
Closing date for public comment: October 14, 2019